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Abstract 
Amorphous solid dispersions are increasingly used in recent years to improve the oral bioavailability of 
poorly water soluble compounds. One technique used for the manufacturing of these systems is hot-melt extrusion. 
This project aimed to investigate the relationship between flexural stress and strain of hot-melt extrudates and 
their milling behavior as well as the effect of formulation composition and particle size on tableting. Three 
different grades of hypromellose (HPMC) were used as polymer and itraconazole (ITZ) served as the model 
compound. 
 For materials that exhibited similar breaking characteristics in a three-point bend test, those with a lower 
maximum flexural stress σM produced a larger proportion of small particles after milling. This decrease in σM was 
correlated to a higher viscosity polymer and higher drug load. After comparing maximum stress and strain with 
milling behavior, there was a first indication that these parameters are linked to each other.  A higher compression 
pressure was necessary to manufacture tablets with the same solid fraction from less elastic extrudate, e.g. HPMC 
4M. Particle size was the most influential factor on the hardness of tablets; smaller particles created tablets with 
higher tensile strength. 
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1. Introduction 
The development of a new medicine is mainly driven by two aspects: efficacy and safety of the product. 
For the technical functions involved in the process, this directly translates into bioavailability, stability and 
manufacturability of the dosage form. Bioavailability is an important factor as it is linked to the pharmacological 
effect and thus efficacy. In addition, the drug product needs to be physically and chemically stable during 
manufacturing and the entire shelf-life. A transformation of the physical state of the drug substance, e.g. formation 
of a less soluble polymorph, could have an impact on the bioavailability. Furthermore, degradation of the 
compound could lead to impurities which might be toxic or less safe in comparison to the drug itself. Finally, drug 
products need to be manufactured on a large scale consistently and efficiently with regards to time as well as cost.  
With the introduction of high throughput screenings in drug discovery, the number of active pharmaceutical 
ingredients (APIs) which exhibit poor aqueous solubility and thus low bioavailability is increasing. Different 
techniques are now available that improve the bioavailability of poorly soluble compounds without dose 
escalation. These methods include chemical modification, physical modification and alternative delivery systems. 
Chemically, a pro-drug can be created which is metabolized in-vivo into the final drug molecule. Physically, a 
polymorph change to a better soluble polymorph can improve bioavailability. Co-solvents and polymeric systems 
are only a few of the possible carrier mechanisms that can help increase the solubility of pharmaceutical 
compounds (Kolter, Karl, & Gryczke, 2012).  
Another type of physical modification is creating an amorphous solid dispersion (ASD). An ASD is defined 
as the dispersion of thermodynamically unstable amorphous API with an inert carrier, often a polymer, in the solid 
state (Shah, Sandhu, Choi, Chokshi, & Malick, 2014). Since solid dispersions usually capture the drug molecule 
in very small particle sizes, they often lead to an improvement in bioavailability (Newman et al., 2012). Several 
technologies for manufacturing ASDs are common in the pharmaceutical industry (Kolter et al., 2012). These 
include spray drying a feed solution of API and polymer dissolved in a common organic solvent (Bend Research, 
2012), freeze-drying or removing solvent through sublimation (Shah et al., 2014), and supercritical fluid drying 
which uses carbon dioxide as the inert medium (Sekhon, 2010). All these methods use solvents which can leave 
unwanted residues in the final drug product requiring a secondary drying step in order to reduce the amount of 
residual solvents until the levels of ICH-guideline Q3C(R5) is reached (ICH, 2011). Using solvents also means 
formulations are restricted by solubility, which in the case of CO2, is especially limited. 
In recent years, there has been a growing interest among researchers in using hot-melt extrusion (HME) to 
produce ASDs. In this method, a powder blend of API, polymer and, in certain cases, plasticizer or other 
processing aids, is heated and mixed with the help of an extruder. Extruders come in two main types, single screw 
and twin screw. Twin screw extruders have a number of advantages over single screw extruders including high 
kneading potential, less tendency to overheat, shorter residence times and high dispersing capacities (Kolter et al., 
2012). The screws have a modular set up with different elements promoting transport and mixing. The material 
moves in the extruder through the following zones: solid feeding, melting, melt conveying, dispersing, 
homogenizing, degassing and discharging (Kolter et al., 2012). Screw elements in the solid feeding, melt 
conveying, degassing and discharging sections are designed to convey material through the machine. In the 
dispersing and homogenizing sections, shear mechanical forces are used to create the ASD (Breitenbach, 2002). 
The mixing and agitation accomplished by parallel rotating screws in these sections causes disaggregation of 
suspended particles in the molten polymer (Shah et al., 2014). Finally, the melt is pushed through a die which can 
be selected to shape the extrudate appropriately for downstream processing. The quality of the extrudate, such as 
API homogeneity can be controlled by in-line processes and analytical tools (PAT) such as Near Infrared or 
Raman Spectroscopy (Kabisch, 2015). A Hot Die Face Pelletizer can be used to cut pellets from the extrudate 
while it is still at an elevated temperature. Otherwise, extrudates need to be cooled on a conveyor before milling 
can take place. After milling, it is possible to compress the extrudate into tablets (Crowley, et al., 2007). 
At each stage of processing between hot-melt extrusion and tablet compression, tests can be run to measure 
physical-mechanical properties of the drug product intermediate. After cooling the extrudate strands, one can test 
for flexural stress and strain through a 3-point bend test. Flexural stress refers to the nominal stress of the outer 
surface of the test specimen at mid-span during a three-point bend test and is a function of the force applied (DIN 
EN ISO 178, 2003). This measurement indicates how elastic or plastic the product is.  A recent study (Kabisch, 
2015) conducted at F. Hoffman La-Roche Ltd. has shown that the composition of the solid dispersion affects the 
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flexural stress of HME extrudates. This change in flexural stress indicates a possible impact on the milling 
behavior of the extrudate (Ho, Cheng, Pan, Wu, & Hsu, 2009; Ozkahraman, 2010; Lu & Siebenmorgen, 1995). 
More elastic products can be more difficult to mill. Instead of producing circular particles with sharp cut edges 
from immediate breakage, elastic material deforms when struck by the blade which can result in irregular particle 
shapes and longer residence time (Fayed & Otten, 2013). Ho et al. have also shown that elastic material can 
damage milling equipment (Ho et al., 2009). 
After sieving, particle size distribution can be measured through a number of different techniques. Most 
commonly, sieve analysis is performed as in-process control to determine the mass of particles that falls within 
certain ranges of diameter. Small samples can also be taken for microscopic analysis. Modern software allows 
these tests to quickly calculate and record relevant parameters such as size distribution by volume, aspect ratio 
and particle shape. Additionally, particle size can be measured using laser diffraction methods. In this technique, 
a laser beam is passed through dispersed particles. The angular scattering produced from the light bouncing off 
the particles is measured and gives a quantative measurement of particle size. For example, large particles scatter 
light at small angles relative to the laser beam and small particles produce larger angles (Malvern, 2015). 
Particle size characterization, meaning the analysis of particle shape, size and size distribution, is important 
in three main stages of pharmaceutical development: formulation development, manufacturing in-process and 
dosage form performance. When developing the formulation, a few large or small particles in an API batch can 
alter the final tablet’s content uniformity, dissolution and/or processing profile.  In-process, flow characteristics 
of formulations are influenced by shape, size and size distribution of particles i.e. large, spherical powders flow 
better than smaller, irregularly shaped particles. From a dosage form performance point of view, particle size and 
distribution are critical in achieving the desired dissolution rate for oral dosage forms (Amidon, Secreast, & 
Mudie, 2009). 
An important parameter of powder manufacturability is flowability, or how well a powder flows in a given 
piece of equipment (Prescott & Barnum, 2000). When powders (or other solid forms) do not discharge well from 
hoppers, bins, glassware, feeding units, etc., problems in the manufacturing process quickly pile up. Outside of 
these efficiency issues, poor flowability can also lead to variability in weight, mixture, and performance properties 
of final powder products (Brookfield). This multifaceted index can be measured in a number of ways. Carr and 
Hausner emphasized the relationship between compressibility and flowability and thus associated the change in 
density when a container holding the powder is tapped to flow character (Carr, 1965). Today, this measurement 
of bulk vs. tapped density is used to give an idea of the flowability of powders and other solid forms. 
Finally, tablets can be compressed from the milled extrudates. Relevant properties of tablets include solid 
fraction and tensile strength. Solid fraction is a measure of how densely packed the particles are, or more 
specifically, what percentage of the tablet volume is occupied by air. Tensile strength is the pressure (force/area) 
necessary to break compact tablets during transverse compression (Iyer, et al., 2013). This measurement is 
important to downstream processing because compacts must be able to withstand the stresses of handling, storage, 
film coating, packaging and transportation (Shang, Sinka, & Jayaraman, 2013). 
This project investigated the relationships between flexural stress of the extrudates, particle size 
distribution, flowability, compressibility (solid fraction vs. compression pressure) and compactibility (tensile 
strength vs. solid fraction) of sieve fractions of the milled extrudates. Analysis of these factors attempted to relate 
measurements taken throughout the manufacturing process of a model system to formulation and downstream 
parameters. In particular, it considered the following questions: 
1. Is the flexural stress of the extrudates dependent on the polymer type and formulation composition 
(e.g. drug load)? 
2. Is the flexural stress of the extrudate related to the particle size & shape of the milled extrudate? 
3. Is the tensile strengths of the tablets manufactured from the milled extrudates dependent on the 
particle size of the extrudate, the polymer type and formulation composition (e.g. drug load)?  
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2. Materials 
For this study, a binary model system (API and a polymer) was selected to investigate the relationship 
between physical and mechanical properties of extrudates and tablets manufactured thereof. These systems are 
also known as second generation amorphous solid dispersions (Vasconcelos, Sarmento, & Costa, 2007). 
Itraconazole (ITZ) is a substance widely studied in literature for amorphous solid dispersions and was thus chosen 
as the model API (DOW Chemical, 2014; United States Pharmacopeia, 2013; Crowley, et al., 2007; Thiry, Krier, 
& Evrard, 2014; Miller, McConville, Yang, Williams, & McGinity, 2007; Verreck, Six, Van den Mooter, Baert, 
Peeters, & Brewster, 2003). ITZ is a white to slightly yellowish powder with a molecular formula of 
C35H38Cl2N8O4, molecular weight of 705.64 g/mol and melting point of 166°C. It is insoluble in water and only 
slightly soluble in alcohols, making ITZ a poorly bioavailable drug. ITZ was purchased from Angene International 
Limited, London, UK (Batch No. 026-016-87, ID# AGN-PC-0USQFP). ITZ is marketed by Janssen 
Pharmaceuticals, Inc. as Sporanox® for the treatment of fungal nail infections (Janssen Pharmaceuticals, Inc., 
2014). The capsules are based on an ASD with hypromellose, or hydroxypropyl methylcellulose (HPMC). 
DOW Chemical has recently launched a new line of HPMC polymers specifically designed for hot-melt 
extrusion (HME) called Affinisol. Since this project focuses on products of HME, different Affinisol HPMC HME 
qualities were selected as the model polymers. They differ in their viscosity and are classified as HPMC 15LV, 
100LV and 4M accordingly. Affinisol HPMC was kindly provided by DOW Wolff Cellulosics GmbH, Bomlitz, 
Germany. Further details on these polymers can be found in Table 2-1. A case study performed by DOW has 
shown that ITZ can successfully formulated using Affinisol HPMC (DOW Chemical, 2014). These HPMC 
polymers have a hydroxypropoxy content of 23.0-32.0% and a methoxy content of 28.0-30.0%. Sodium chloride 
is a known side product of the synthesis of Affinisol HPMC. 
 
Table 2-1: Chemical properties of Affinisol HPMC from DOW Chemical 
Polymer Type Batch No. Viscosity 
(mPa*s) 
Molecular Weight 
(kDa) 
Determined Glass Transition 
(°C) 
Source DOW Chemical DOW Chemical DOW Chemical Roche lab 
(DOW Chemical: 115-120°C) 
HPMC 15LV F293F2C001 15 50-75 97 
HPMC 100LV F293F2D001 100 140-190 100 
HPMC 4M F293F2D002 4000 400-600 105 
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3. Methods 
3.1 Manufacturing 
3.1.1 Formulation Composition and Blending 
Mixtures of Affinisol HPMC HME polymers and itraconazole (ITZ) were prepared by blending the required amount of API and polymer in a Turbula T2F 
Shaker-Mixer (GlenMills, NJ) for 3 minutes.  
 
Table 3-1 Formulation composition (ingredient amounts in grams) 
Ingredients Batch No. 
150622_SS_02 150624_SS_03 150625_SS_04 150629_SS_05 150727_SS_06 150728_SS_07 150729_SS_08 150803_SS_11 150731_SS_10 150730_SS_09 
ITZ 480.03 240.50 59.99 -- 400.77 200.95 50.12 400.10 200.80 20.07 
HPMC 15LV 720.01 959.79 1139.79 1000.52 -- -- -- -- -- -- 
HPMC 100LV -- -- -- -- 599.42 800.09 950.01 -- -- -- 
HPMC 4M -- -- -- -- -- -- -- 600.64 800.10 379.81 
Total 1200.04 1200.29 1199.78 1000.52 1000.19 1001.04 1000.13 1000.74 1000.90 399.88 
Drug Load 40% 20% 5% Placebo 40% 20% 5% 40% 20% 5% 
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3.1.2 Hot-Melt Extrusion 
Extrudates were manufactured from pre-blends containing Affinisol HPMC and ITZ (for composition, see 
Table 3-1) using a 12 mm standard twin screw extruder from Brabender (DSE 12/36, Duisberg, Germany, 
Software: Brabender Extruder Program for Windows CAN Version 4.3.0) with a die having an orifice diameter 
of 8 mm. The barrel temperature in Zones 2 through 4 were set to 175°C in case of Affinisol HPMC 15LV and 
increased to 190°C for HPMC 100LV and 4M due to their higher melt viscosity. As a reference, a placebo 
extrudate was manufactured using HPMC 15LV. The process parameters for the HPMC 15LV, 100LV and 4M 
containing formulations are depicted in Table 3-2, Table 3-3, and Table 3-4, respectively.  
 
Table 3-2: Summary of process parameters for Hot-Melt Extrusion of HPMC 15LV + ITZ drug loads. 
HPMC 15LV + 40% ITZ + 20% ITZ + 5% ITZ Placebo 
Temp Zone 1 (°C) 90-175 110-130 100-110 100-110 
Temp Zones 2-4 (°C) 175 175 175-178 175 
Average Screw Speed 
(rpm) 
118.8 131.6 130.0 131.3 
Maximum Screw Speed 
(rpm) 
140 140 130 140 
Screw Speed of Feeding 
Unit (rpm) 
30-40 35-40 30-40 25-30 
Observations and Visual 
Appearance 
Glassy, hard, 
lightest color 
Darker color than the 40% 
but lighter than the 5%. 
Not glassy 
Very dark Very dark 
 
Table 3-3 Summary of process parameters for Hot-Melt Extrusion of HPMC 100LV + ITZ drug loads 
HPMC 100LV + 40% ITZ + 20% ITZ + 5% ITZ 
Temp Zone 1 (°C) 110-130 110-130 100-130 
Temp Zones 2-4 (°C) 175-190 190 190 
Average Screw Speed 
(rpm) 
135.8 141.4 140.7 
Screw Speed of Feeding 
Unit (rpm) 
52* 40-45 35, 60** 
Observations and Visual 
Appearance 
“shark skin” 
on product, poor flow 
 Problems with 
feeding screws 
*Average. 
**One screw in feeding unit stopped working. Feed rate input to software increased to compensate. 
 
Table 3-4 Summary of process parameters for Hot-Melt Extrusion of HPMC 4M + ITZ drug loads 
HPMC 4M + 40% ITZ + 20% ITZ + 5% ITZ 
Temp Zone 1 (°C) 100-170 110-120 100-130 
Temp Zones 2-4 (°C) 190 190 190 
Average Screw Speed 
(rpm) 
135.8 141.4 140.7 
Screw Speed of Feeding 
Unit* (rpm) 
8-13 10-13 8-10 
 Observations and Visual 
Appearance 
Dark yellow product 
sometimes with white 
stripes; 
problems with bridging 
Dark yellow, light brown 
product, sometimes with 
white stripes; 
problems with bridging 
Brown product 
*New feeding screws  
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Process parameters were adjusted throughout extrusions to maintain similar throughput, volume specific 
feed load (VSFL) and specific mechanical energy consumption (SMEC) so the processes would be comparable 
across batches. The screw configuration was kept constant between batches. By maintaining a similar VSFL, only 
changes in polymer type and drug load would influence the resulting product, not the extrusion process itself. 
VSFL can be calculated using the following equation where ?̇? is the throughput in g/min, 𝑉𝑓𝑟𝑒𝑒 is the free volume 
of the extruder with a constant screw configuration in cm3 and 𝑛  is the screw speed in rpm. 
𝑉𝑆𝐹𝐿 =
?̇?
𝑉𝑓𝑟𝑒𝑒 ∙ 𝑛
 
Specific mechanical energy consumption (SMEC) is a measure of the energy applied to the material and is 
another method for comparing HME processes. It can be calculated using the following equation where 𝜏 is the 
torque in Nm. 
𝑆𝑀𝐸𝐶 =
2 ∙ 𝜋 ∙ 𝑛 ∙ 𝜏
?̇?
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3.1.3 Milling 
Extrudates were cut into small pieces (2 to 5 cm in length) and milled using a Hammerwitt-Lab mill from 
Frewitt (Granges-Paccot, Switzerland), rotating at 4000 rpm with the hammer forward. The milling process was 
performed in a 3-step method. First, cut extrudates were milled with a 5 mm screen. A sample of the milled 
product was taken for Particle Size Distribution (PSD) analysis and the rest was milled again with a 3 mm screen. 
Another sample of the resulting product was taken for PSD and the remaining product was milled again using a 2 
mm screen. This final product was also sampled for PSD measurement. 
3.1.4 Sieving 
Milled extrudate (100 g at a time) was sieved using an AS300 Control Sieving Machine from RETSCH 
(Retsch GmbH, Haan, Germany) with amplitude of 2.00 mm for 5 minutes. The sieve tower was made of eight 
sieves measuring 1.00 mm, 710 μm, 500 μm, 355 μm, 250 μm, 180 μm, 125 μm, 90 μm and a base where particles 
smaller than 90 μm were collected. Each sieve fraction was weighed and collected. In order to investigate the 
impact of the particle size, the sieve fractions 500 μm-710 μm, 250 μm - 355 μm and 90 μm – 180 μm were 
selected for further analysis and downstream processing. 
3.1.5 Tablet Compression 
Tablets were compressed using a Hydraulic Press from Perkin-Elmer (Baesweiler, Germany) with a Micra-
M Digital Counter from Messtechnik Schaffhausen GmbH (Stein am Rhein, Neuhausen, Switzerland) attached. 
For each tablet, 250 mg of milled extrudate was transferred into a 9 mm round die and pressed with 3-15 kN of 
force using biplane punches to create tablets with low, medium and high solid fractions (see Table 3-5). Twenty-
seven tablets from each batch were made; three tablets at each of three solid fractions for three sieve fractions per 
formulation. 
 Solid fraction was analyzed using a Laser-based Solid Fraction Measurement System from Custom Lab 
Software Systems, Inc. (Centerbrook, Connecticut, USA). This machine scans individual tablets with a laser to 
determine volume, Vlaser, and weighs them. The software calculates solid fraction according to the following 
equation, taking into account the true density (δtrue) input from the user. 
𝑠𝑜𝑙𝑖𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =  
𝑉𝑡𝑟𝑢𝑒
𝑉𝑔𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐
 
 Solid fractions were classified according to Table 3-5 (Iyer, et al., 2013; University of Michigan, College 
of Pharmacy, 2011). 
Table 3-5 Classification of Solid Fractions 
Solid Fraction Classification 
0.80 – 0.82 Low 
0.84 – 0.86 Medium 
0.88 – 0.90 High 
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3.2 Characterization of Extrudates 
3.2.1 Three-Point Bend Test 
The 3-point bend test was performed in order to investigate flexural stress and strain of the extrudates 
according to DIN EN ISO 178. The test setup consisted of two support pins and a loading pin, all three having a 
radius of 5 mm. The support pins were manufactured to be 10 cm tall with notches of 10 mm diameter to stabilize 
the sample during testing. To comply with the DIN ISO 178:2010 standard, the support distance must be 12 times 
the specimen thickness h, thus the diameter of the cylindrical extrudates was measured and the distance between 
support pins adjusted accordingly.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1: Diagram of 3-Point Bend Test Apparatus (DIN EN ISO 178, 2003) 
The tests were performed with the TA.XTPlus Texture Analyzer (Stable Micro Systems, Ltd., Surrey,UK, 
Software: Exponent from Stable Micro Systems Version 6.0.7.0) using a 50 kg load cell. Due to the elasticity of 
the HPMC extrudates, the test speed was set to 10 mm/min. While the loading pin moves with the given speed, 
the Texture Analyser system measured the force and displacement until the sample broke or the maximum distance 
was reached.  
According to the DIN ISO 178, when analyzing data from three-point bend tests, there are two important 
parameters which describe the material. First, the flexural stress σ is calculated using the force F in Newton, the 
support distance L in mm, and the radius of the circular cross-section R in mm (Chapter 4: Mechanical Properties 
of Biomaterials, 2008). Flexural stress is the force per area (N/mm2) which can also be given in Pascal (N/m2). 
𝜎 =
𝐹𝐿
𝜋𝑅3
 
Second, flexural strain ε is a measure of how far the sample has bent relative to the support distance. Percent 
flexural strain can be calculated with the following equation where ε is the flexural-strain parameter expressed as 
a percentage, s is the distance in mm that the loading pin has travelled, h is the thickness of the sample in mm, 
and L is the support distance in mm.  
𝜀 =
600𝑠ℎ
𝐿2
% 
Both flexural stress σ and strain ε can be calculated at the point where maximum force is applied (εfM, σfM) 
and at the breaking point (εfB, σfB). Three samples of each extrudate batch were measured. Most curves matched 
the model Curve b from Figure 3-2 below; however, some samples broke at the maximum level of force, resulting 
in graphs resembling Curve a. All values given for flexural stress σfM, σfB and flexural strain εfM, εfB represent 
an average of the three measurements. 
Legend 
1 Specimen 
F Force [N] 
R1 radius of loading edge [mm] 
R2 radius of the supports [mm] 
h thickness of specimen [mm] 
l length of specimen [mm] 
L adjusted distance of supports 
[mm] 
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Figure 3-2: Typical curves of flexural stress vs. flexural strain (DIN EN ISO 178, 2003) 
3.3 Characterization of Milled Extrudates 
3.3.1 XRPD 
X-ray diffraction patterns were recorded at ambient conditions in transmission geometry with a STOE 
STADI P diffractometer (Cu Ka radiation, high voltage 40kV, electric current 40 mA, Ge monochromator, 
silicon strip detector, angular range 3° to 42° 2Theta, approximately 30 minutes total measurement time). The 
samples were prepared and analyzed without further processing (e.g. grinding or sieving) of the substance. 
3.3.2 Particle Size Distribution 
Samples taken after each milling step were sieved through a 1.00 mm screen. The particle size distribution 
of the fraction of particles smaller than 1.00 mm in diameter was measured in triplicate by a Mastersizer 3000 
Dry Laser Diffraction System with a Malvern Aero S dispenser and Mastersizer software version 3.10 (Malvern 
Instruments Limited, Malvern, Worcestershire, UK). The analysis yielded the percent by volume below specific 
diameters which was converted to mass percent using absolute density measurements (see Method 3.2.5). This 
information, in conjunction with the mass above 1.00 mm, was used to develop a size distribution for each sample 
and milling step. 
3.3.3 Bulk and Tapped Density 
Samples of 20 g from each sieve fraction of milled extrudate were poured into a 100 mL graduated cylinder 
and the volume recorded as V0 or bulk volume. The graduated cylinder was mounted to a Stampfvolumeter JEL 
“Stav 2003", and tapped 2500 times to give V2500. Bulk density was calculated as 
𝑚
𝑉0
 in g/mL. Tapped density was 
calculated as 
𝑚
𝑉2500
 in g/mL.  
The compressibility index, or Carr index after the pharmacologist Charles Carr (1910-2005), measures the 
relative significance of interparticle interactions. This, along with the Hausner ratio, was calculated after 
determining the bulk and tapped density of a material. In combination, these parameters give an indication of the 
flowability of a powder. The Carr index and can be calculated with the following equation. 
𝐶𝐼 = 100 ×
𝑉0 − 𝑉2500
𝑉0
 
Likewise, the Hausner ratio can be calculated as follows: 
15  
𝐻𝑅 =  
𝑉0
𝑉2500
 
It is important to note that these measurements are not an absolute property of the material, but are 
dependent on the methodology used to determine them. Small sample sizes of the fine sieve fraction most likely 
resulted in skewed measurements. 
3.3.4 True Density 
Two samples of approximately 4 g of each batch of milled extrudate were tested in an AccuPyc 1330 V3.03 
He-Pycnometer from Micromeritics Instrument Co. (Micromeritics Germany GmbH, Aachen, Germany) to 
measure the true density. These two results for each drug load were averaged to obtain the true density. 
3.4 Characterization of Tablets 
3.4.1 Tensile Strength 
Tablets were tested for hardness using a SOTAX HT 100 Automatic Tablet Testing System (SOTAX AG, 
Aesch, Switzerland) and q-doc 3cSP2 software v.3.07. Afterwards, the tensile strength was calculated by dividing 
the hardness by the cross-sectional area of the tablets. 
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4. Results 
4.1 Hot-Melt Extrusion 
Extrusion processes were checked for comparability by measuring the torque and throughput to calculate 
VSFL and SMEC. Tables of these measurements can be found in Appendix Figures 6-1, 6-2 and 6-3. Extrusions 
of product with a 40% drug load of ITZ generally had a lower VSFL and extrusions of HPMC 100LV products 
had higher SMEC values. However, all values for VSFL and SMEC are similar and remain in an acceptable 
range to consider the processes comparable. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 VSFL vs. Drug Load 
  
Figure 4-2 SMEC vs. Drug Load 
4.2 Initial Characterization – XRPD 
Despite the visual observations made during hot-melt extrusion (see Table 3-2, Table 3-3, and Table 3-4) 
all extrudates showed the typical amorphous halo with an additional distinct peak at 32.0 2Theta. This peak was 
present already in the unprocessed polymer, and can be attributed to sodium chloride, which is a side product of 
the synthesis of the polymer (information obtained from DOW Chemicals). Figure 4-3 shows an overlay of the 
X-ray pattern of HPMC 15LV + ITZ drug loads, placebo and crystalline Itraconazole. The results of all other 
batches is shown in Table 6-4 in the Appendix. 
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Figure 4-3 XRPD overlay of HPMC 15LV + ITZ drug loads, placebo and crystalline ITZ. 
4.3 Flexural Stress and Strain 
Figure 4-4 gives an example of the data obtained from the 3-point bend test. Overall, the extrudates showed 
a different fracture behavior in the 3-point bend test. Some extrudates were so elastic that no breakage was 
observed. Others first reached a maximum of the force before breakage was observed at a lower force and others 
broke at maximum force. 
 At these two distinct points of interest, e.g. when maximum force is applied and when the extrudate breaks, 
the force (y-axis) was used to calculate flexural stress σ and because the loading pin moves at a constant speed, 
the time (x-axis) was used to calculate flexural strain ε. The averages of these calculations (n=3) can be found in 
Table 6-5 in the Appendix. 
The flexural strain M varied between 6 and 9% for the extrudates with HPMC 15LV and HPMC 100LV, 
whereas for the extrudates containing HPMC 4M values between 3 and 4% were determined. This indicates that 
the low molecular weight HPMC grades are more elastic compared to the high molecular weight grade (HPMC 
4M). 
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Figure 4-4: Graphical results of force vs. time for three-point bend test of HPMC 15LV batches 
Figure 4-5 summarizes the results for the three-point bend test by showing the values for flexural stress σ 
at both maximum force and breaking point. It could be observed that the HPMC 15LV and 100LV polymers had 
similar breaking character. These extrudates broke after reaching maximum force and deformation (σB < σM) but 
at higher drug loads, σB approached σM and deformation decreased. Increasing drug load in these polymers also 
lead to an increase in σ. The HPMC 4M extrudates demonstrated a completely different fracture behavior, where 
all drug loads broke at maximum force with little deformation. All drug loads of HPMC 4M gave similar values 
of σ which were significantly lower than the flexural stresses of HPMC 15LV and 100LV extrudates. 
When comparing extrudates with the same drug load, for example the 20%ITZ extrudates, it could be 
observed that polymers with higher molecular weight and viscosity resulted in lower σ measurements. 
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Figure 4-5 Flexural Stress vs. Drug Load for all HPMC + ITZ batches.  
4.4 Particle Size Distribution 
Based on a milling pre-test performed, it was decided to exclude the batches containing 5% ITZ of HPMC 15LV and 100LV from the main trial due to the fact that 
a large amount of material remained in the mill itself (above the screen), which leads at longer run time to melting of the extrudate strands and potential damage of the 
equipment. All other batches were milled as described in the method section and the particle size distribution was analyzed. 
The initial fracture of the extrudate takes place during the first milling step. It can therefore be expected that the fracture behavior of the extrudates is reflected in 
the amount of particles below 1 mm after the first milling cycle with a 5 mm screen. Figure 4-6 shows the mass percent of samples taken from the first milling cycle with 
a 5 mm screen that have a diameter below 1.00 mm. The amount of particles below 1 mm differ for the investigated extrudates. 
In order to relate the particle size results to the mechanical properties explored in the three point bend test, the extrudates were divided into groups depending on 
their breaking characteristic: 
 Extrudate broke after deformation (σB < σM) 
 Extrudate broke at or near maximum force (σB ≈ σM and σB = σM, respectively) 
Extrudates containing 15LV or 100LV at 20% drug load of ITZ broke after deformation (σB < σM) as shown in Figure 4-5. From Figure 4-5, it is also noted that the 
100LV + 20% drug load extrudate had a lower σM. This resulted in a higher proportion of small particles (<1 mm) than compared to the HPMC 15LV + 20% drug load 
as depicted in Figure 4-6. 
All extrudates with a 40% drug load of ITZ broke at or near maximum force (σB ≈ σM). At this drug load, the higher the molecular weight and viscosity of the 
HPMC polymer, the lower the observed flexural stress σ. A lower the flexural stress of the extrudate at this drug load was again linked to a higher proportion of small 
particles (<1 mm). 
All HPMC 4M extrudates at the investigated drug loads between 5% and 40% ITZ broke at maximum force, σB = σM, and at similar values of σ, between 300 MPa 
and 400 MPa. Likewise a similar proportion of small particles (<1 mm) was obtained for all HPMC 4M milled extrudates, ranging between 40% and 50%. 
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Figure 4-6 Particle Size vs. Drug Load. Mass % less than 1mm in 
diameter after sieving samples from the first (5mm) milling cycle. 
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Figure 4-5 Particle Size Distribution from Laser Diffraction measurements. On Left, samples from after 5mm milling step. On right, 
samples from after 2mm milling step. Samples from after 3mm milling step can be found in Appendix Figure 6-2. 
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4.5 Flowability 
The results of the bulk and tapped density measurements were used for the calculation of the 
Compressibility Index as well as Hausner Ratio, which are shown in Figure 4-6. Higher values for 
Compressibility Index and Hausner Ratio indicate poor flow character. Despite small sample sizes for the fine 
sieve fraction (90-180 μm), the data supports the generalization that smaller particles have poorer flow 
character. Particle size seems to be the determining factor of flowability. However, it is interesting to note that 
in the HPMC 4M data set, a higher drug load results in better flow character in the medium and coarse sieve 
fractions. Since these results are from small sample sizes with no repeated trials, further studies are needed to 
confirm this relationship between drug load and flowability. 
 
 
 
 
Figure 4-6 Flowability characterized by Hausner Ratio (left y-axis, solid bars) and Compressibility Index (right y-axis, striped 
bars). The higher either of these values is, the worse the flowability of the powder. *low sample size (<10g). **sample too small for 
measurement. n=1 
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4.6 Compressibility 
Tablets were manufactured from the milled extrudates containing 20% ITZ and 40% ITZ. No tablets were 
obtained from milled extrudate of HPMC 15LV + 40% ITZ with particle size of 500-710 μm. Interestingly, this 
extrudate was the one with the highest flexural stress at maximum and breakage of all tested extrudates. 
Figure 4-7 maps the compression pressure used to manufacture tablets and the solid fraction obtained. In 
general, a higher compression pressure was needed to make tablets form the HPMC 4M milled extrudate. This 
could be related to the breaking behavior observed in the 3-point bend test. The HPMC 4M extrudates did not 
exhibit the same elastic behavior as the HPMC 15LV and 100LV. Since compressibility is the ability of a 
powder to deform under pressure, it logically follows that the more elastic extrudates would require lower 
compression pressures (Rai, Kale, Maske, Raut, & Chntale, 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 Compressibility of Tablets. In general, the milled 4M extrudates required a higher compression pressure. 
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4.7 Compactibility 
Tablets with higher tensile strength were obtained from the smaller particles (90-180μm). This is due to 
the increased surface area to volume ratio of smaller particles, enabling more interparticle bonds to form. In the 
pharmaceutical industry, a tensile strength of more than 1 MPa is necessary to make a satisfactory tablet. By this 
standard, all tablets made from the coarse sieve fraction (500-710 μm) were not acceptable. 
 
     
 
 
Figure 4-8 Compactibility of Tablets. In general, higher tensile strengths were obtained from tablets made with smaller particles. 
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5. Conclusion 
This project investigated the relationship between formulation composition and physical mechanical 
properties of HME extrudates. Most especially, a connection between a 3-point bend test and milling behavior 
was explored. 
For the tested binary model of hot-melt extrudates, it was concluded that between materials that exhibit 
similar breaking characteristics in a three-point bend test, those with a lower maximum flexural stress σM will 
produce a larger proportion of small particles after milling. For two polymers, HPMC 15LV and 100LV, a 
higher drug load resulted in a lower σM and at two drug loads, 20% and 40%, a higher viscosity polymer resulted 
in a lower σM. It appears that from a formulation composition perspective, polymer type had a greater effect on 
flexural strain and stress than drug load. However, it should be noted that other factors can affect results from a 
3-point bend test. In fact, most HMEs generally include plasticizers to improve processibility. Other methods of 
investigating elasticity and mechanical properties of extrudates and their connection with milling behavior 
should be explored. 
When analyzing milling performance, this study relied on particle size distribution and observations made 
in the lab. It would be helpful to also analyze the yield between milling steps. Milling time could also be 
controlled in order to ensure comparable processes or measured as an indicator of milling performance. 
 Data obtained in this study also supported the theory that small particles reduce flowability (Carr, 1965). 
Smaller particles have a larger surface area to volume ratio and therefore are more susceptible to cohesive 
forces. 
It was determined that a higher compression pressure was necessary to manufacture tablets from less 
elastic extrudate, e.g. HPMC 4M. Particle size was the most influential factor on the tensile strength of tablets; 
smaller particles created tablets with higher tensile strength. However, outside of this binary model system, 
tablets usually do not only consist of milled extrudates but also contain disintegrants and fillers. These 
excipients will have an additional impact on the properties of tested tablets.  
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6. Appendix 
 
Table 6-1 Measured Parameters for Hot-Melt Extrusion of HPMC 15LV + ITZ drug load batches 
HPMC 15LV + 40% ITZ + 20% ITZ + 5% ITZ Placebo 
Torque [Nm] 6.77 8.98 10.25 10.18 
Throughput 
[
𝐠
𝐦𝐢𝐧⁄ ] 
3.32 4.91 5.22 5.32 
VSFL ratio 
[
𝐠
𝐜𝐦³
⁄ ] 
0.81× 10−3 1.08× 10−3 1.16× 10−3 1.17× 10−3 
SMEC 
[𝐤𝐖𝐡 𝐤𝐠⁄ ] 
1.52 1.51 1.60 1.58 
 
Table 6-2 Measured Parameters for Hot-Melt Extrusion of HPMC 100LV + ITZ drug load batches 
HPMC 100LV + 40% ITZ + 20% ITZ + 5% ITZ 
Torque [Nm] 7.55 9.32 10.31 
Throughput 
[
𝐠
𝐦𝐢𝐧⁄ ] 
3.89 4.91 5.11 
VSFL ratio 
[
𝐠
𝐜𝐦³
⁄ ] 
0.84× 10−3 1.01× 10−3 1.05× 10−3 
SMEC 
[𝐤𝐖𝐡 𝐤𝐠⁄ ] 
1.65 1.69 1.78 
 
Table 6-3 Measured Parameters for Hot-Melt Extrusion of HPMC 4M + ITZ drug load batches 
HPMC 4M + 40% ITZ + 20% ITZ + 5% ITZ 
Torque [Nm] 7.22 8.50 9.90 
Throughput 
[
𝐠
𝐦𝐢𝐧⁄ ] 
4.32 4.95 5.03 
VSFL ratio 
[
𝐠
𝐜𝐦³
⁄ ] 
0.91× 10−3 1.04× 10−3 1.03× 10−3 
SMEC 
[𝐤𝐖𝐡 𝐤𝐠⁄ ] 
1.44 1.49 1.75 
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Table 6-4 XRPD Characterization of HPMC 100LV and HPMC 4M Extrudates 
Polymer Drug Load ITZ Batch No. XRPD Characterization 
HPMC 15LV 5% 150625_SS_04 Amorphous 
 20% 150624_SS_03 Amorphous 
 40% 150622_SS_02 Amorphous 
HPMC 100LV 5% 150729_SS_08 Amorphous 
20% 150728_SS_07 Amorphous 
40% 150727_SS_06 Amorphous 
HPMC 4M 5% 150730_SS_09 Amorphous 
20% 150731_SS_10 Amorphous 
40% 150803_SS_11 Amorphous 
 
 
 
Table 6-5 Average Flexural Stress σ and Strain ε 
Polymer Drug Load 
(ITZ) 
Average 
σM 
(MPa) 
StDev 
σM 
Average 
σB 
(MPa) 
StDev 
σB 
Average 
εM % 
Stdev 
εM 
Average 
εB % 
Stdev 
εB 
HPMC 
15LV 
0% 366.95 6.5   9% 1%   
5% 418.59 10.7   7% 0%   
20% 580.21 19.1 496.04 17.9 7% 0% 12% 0% 
40% 645.15 46.4 637.59 39.2 6% 1% 7% 1% 
HPMC 
100LV 
5% 433.05 7.5   8% 0%   
20% 530.50 26.0 417.79 46.2 7% 0% 16% 0% 
40% 609.36 14.3 609.36 14.3 7% 0% 7% 0% 
HPMC 
4M 
5% 326.08 10.3 326.08 10.3 4% 0% 4% 0% 
20% 381.74 28.9 381.74 28.9 4% 0% 4% 0% 
40% 373.47 27.0 373.47 27.0 3% 0% 3% 0% 
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Figure 6-1 Sieve Analysis for all batches 
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Figure 6-2 Particle Size Distribution by Laser Diffraction of Particles Smaller than 1 mm in Diameter after Second Milling Step 
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Polymer Drug 
Load 
Sieve 
Fraction 
(μm) 
Mass 
(g) 
V0 
(mL) 
V2500 
(mL) 
D0 
(g/mL) 
D2500 
(g/mL) 
CI HR CI Class HR Class 
HPMC 
15LV 
20% 90-180 20.06 55 38 0.36 0.53 44.7 1.45 Very, very poor Poor 
 250-355 20.05 47 40.5 0.43 0.50 16.0 1.16 Fair Good 
 500-710 20.08 43 40 0.47 0.50 7.5 1.08 Excellent Excellent 
40% 90-180 18.25 45 33 0.41 0.55 36.4 1.36 Very poor Poor 
 250-355 20.03 40.5 35 0.49 0.57 15.7 1.16 Good Good 
 500-710 20.06 35 32 0.57 0.63 9.4 1.09 Excellent Excellent 
HPMC 
100LV 
20% 90-180 7.47 20.5 15 0.36 0.50 36.7 1.37 Very poor Poor 
 250-355 20 46 42 0.43 0.48 9.5 1.10 Excellent Excellent 
 500-710 20 46.5 40.5 0.43 0.49 14.8 1.15 Good Good 
40% 90-180 5.407 13 11 0.42 0.49 18.2 1.18 Fair Good 
 250-355 20.02 42 37.5 0.48 0.53 12.0 1.12 Good Good 
 500-710 20.01 41 35.5 0.49 0.56 15.5 1.15 Good Good 
HPMC 
4M 
5% 90-180 2.85 9  0.32      
 250-355 11.18 28.5 23 0.39 0.49 23.9 1.24 Good Good 
 500-710 20.02 46 38 0.44 0.53 21.1 1.21 Good Good 
20% 90-180 6.13 16 12.5 0.38 0.49 28.0 1.28 Poor Passable 
 250-355 20.03 50 41 0.40 0.49 22.0 1.22 Passable Fair 
 500-710 20.07 42 37.5 0.48 0.54 12.0 1.12 Good Good 
40% 90-180 7.14 18.5 14 0.39 0.51 32.1 1.32 Very poor Passable 
 250-355 20.01 42 37 0.48 0.54 13.5 1.14 Good Good 
 500-710 20.06 39 35 0.51 0.57 11.4 1.11 Good Excellent 
 
 
  
30  
 
Table 6-6 Compression Force and Solid Fractions of Tablets 
Polymer Drug Load 
ITZ 
Sieve 
Fraction 
SF class Force (N) Solid 
fraction 
SF StDev SF RSD Pressure 
(MPa) 
HPMC 
15LV 
20% 500-710 low 3 0.813 0.005 0.006 47.2 
med 6 0.865 0.004 0.005 94.3 
high 10 0.902 0.002 0.003 157.2 
250-355 low 4 0.815 0.013 0.016 62.9 
med 6 0.856 0.012 0.014 94.3 
high 10 0.888 0.003 0.003 157.2 
90-180 low 3 0.809 0.003 0.004 47.2 
med 4 0.848 0.011 0.013 62.9 
high 7 0.888 0.002 0.002 110.0 
40% 500-710 low     0.0 
med 4 0.862 0.007 0.008 62.9 
high 4.5 0.885 0.011 0.012 70.7 
250-355 low 3 0.802 0.009 0.012 47.2 
med 4.5 0.850 0.011 0.012 70.7 
high 6 0.891 0.003 0.004 94.3 
90-180 low 4 0.814 0.016 0.020 62.9 
med 5 0.850 0.012 0.014 78.6 
high 6 0.876 0.001 0.001 94.3 
HPMC 
100LV 
20% 500-710 low 3 0.820 0.013 0.016 47.2 
med 4 0.846 0.006 0.007 62.9 
high 6.5 0.892 0.006 0.006 102.2 
250-355 low 4 0.813 0.005 0.006 62.9 
med 5 0.850 0.005 0.006 78.6 
high 6.5 0.879 0.003 0.003 102.2 
90-180 low 3.5 0.810 0.004 0.005 55.0 
med 4.5 0.858 0.014 0.016 70.7 
high 6 0.882 0.004 0.004 94.3 
40% 500-710 low 3.5 0.811 0.013 0.017 55.0 
med 4 0.848 0.008 0.009 62.9 
high 5 0.881 0.001 0.001 78.6 
250-355 low 3 0.804 0.014 0.017 47.2 
med 4.5 0.847 0.007 0.008 70.7 
high 8 0.896 0.003 0.004 125.8 
90-180 low 3 0.801 0.006 0.008 47.2 
med 4.5 0.853 0.013 0.015 70.7 
high 8 0.879 0.005 0.006 125.8 
HPMC 
4M 
20% 500-710 low 4 0.811 0.012 0.014 62.9 
med 6 0.847 0.006 0.007 94.3 
high 9 0.885 0.009 0.010 141.5 
250-355 low 4.5 0.806 0.008 0.009 70.7 
med 8 0.856 0.005 0.006 125.8 
high 12 0.888 0.007 0.008 188.6 
90-180 low 3.5 0.815 0.006 0.008 55.0 
med 4.5 0.850 0.010 0.012 70.7 
high 9 0.883 0.005 0.005 141.5 
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40% 500-710 low 4 0.813 0.010 0.012 62.9 
med 5.5 0.850 0.012 0.014 86.5 
high 9 0.888 0.019 0.021 141.5 
250-355 low 4.5 0.815 0.013 0.016 70.7 
med 5.5 0.848 0.000 0.000 86.5 
high 8.5 0.881 0.007 0.008 133.6 
90-180 low 3.5 0.807 0.015 0.019 55.0 
med 4.5 0.845 0.006 0.007 70.7 
high 7 0.881 0.006 0.006 110.0 
5% 500-710 low 4 0.806 0.008 0.010 62.9 
med 6 0.850 0.012 0.014 94.3 
high 11 0.881 0.006 0.007 172.9 
250-355 low 4 0.807 0.007 0.009 62.9 
med 8 0.850 0.009 0.011 125.8 
high 12.5 0.875 0.001 0.001 196.5 
90-180 low 4 0.807 0.000 0.000 62.9 
med 5.5 0.839 0.003 0.003 86.5 
high 10.5 0.879 0.004 0.005 165.0 
 
 
Table 6-7 Hardness and Tensile Strength of Tablets 
Polymer Drug Load 
ITZ 
Sieve 
Fraction 
Solid 
Fraction 
Hardness 
(N) 
n Hardness 
StDev 
Hardness 
RSD 
Thickness 
(mm) 
Tensile 
Strength 
(MPa) 
15LV 20% 500-710 low 23.00 1   4.2 0.61 
med 36.50 2 3.54 0.097 3.8 1.06 
high 37.00 3 2.65 0.072 3.8 1.07 
250-355 low 39.33 3 3.06 0.078 4.1 1.08 
med 53.67 3 3.21 0.060 3.9 1.53 
high 65.33 3 2.31 0.035 3.8 1.93 
90-180 low 52.00 3 4.36 0.084 4.0 1.44 
med 61.67 3 12.1 0.195 3.8 1.80 
high 76.67 3 1.53 0.020 3.6 2.34 
40% 500-710 low  3     
med  3   4.2  
high  3   4.1  
250-355 low 24.00 3 2.00 0.083 4.1 0.64 
med 30.67 3 3.51 0.115 3.9 0.88 
high 44.33 3 4.93 0.111 3.7 1.33 
90-180 low 58.00 3 11.4 0.196 3.9 1.66 
med 72.00 3 6.00 0.083 3.8 2.13 
high 87.33 3 4.04 0.046 3.7 2.65 
100LV 20% 500-710 low 16.00 1   4.2 0.42 
med 19.00 2 2.83 0.149 4.0 0.53 
high 27.67 3 1.53 0.055 3.9 0.78 
250-355 low 31.00 3 2.65 0.085 4.1 0.84 
med 41.33 3 4.16 0.101 3.9 1.17 
high 51.33 3 0.58 0.011 3.8 1.49 
90-180 low 53.33 3 1.53 0.029 4.0 1.49 
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med 72.33 3 7.37 0.102 3.8 2.10 
high 75.33 3 2.52 0.033 3.7 2.26 
40% 500-710 low 14.00 1   4.1 0.38 
med 21.67 3 3.51 0.162 4.0 0.60 
high 29.33 3 5.13 0.175 3.9 0.84 
250-355 low 36.00 3 3.46 0.096 4.1 0.99 
med 50.67 3 1.15 0.023 3.9 1.45 
high 64.67 3 1.53 0.024 3.7 1.96 
90-180 low 49.67 3 1.15 0.023 4.0 1.39 
med 72.00 3 4.00 0.056 3.8 2.08 
high 82.00 3 3.46 0.042 3.7 2.44 
4M 20% 500-710 low 15.00 1   4.2 0.40 
med 18.33 3 4.04 0.220 4.2 0.49 
high 24.67 3 1.53 0.062 3.9 0.71 
250-355 low 31.67 3 1.53 0.048 4.1 0.86 
med 41.33 3 3.21 0.078 3.9 1.18 
high 52.67 3 4.16 0.079 3.8 1.55 
90-180 low 45.00 3 2.65 0.059 4.0 1.25 
med 59.67 3 5.51 0.092 3.8 1.74 
high 73.00 3 1.73 0.024 3.7 2.17 
40% 500-710 low 15.50 2 0.71 0.046 4.1 0.42 
med 24.00 1   4.0 0.67 
high 28.00 3 7.00 0.250 3.9 0.79 
250-355 low 37.33 3 4.62 0.124 4.0 1.03 
med 41.33 3 2.52 0.061 3.8 1.20 
high 58.33 3 2.52 0.043 3.7 1.76 
90-180 low 50.67 3 9.29 0.183 3.9 1.43 
med 61.67 3 6.03 0.098 3.7 1.83 
high 85.33 3 7.64 0.090 3.6 2.66 
5% 500-710 low 14.00 1  0.000 4.3 0.36 
med 16.67 3 2.31 0.139 4.2 0.44 
high 17 3 2.65 0.156 4.0 0.47 
250-355 low 22.66667 3 5.03 0.222 4.3 0.59 
med 30 3 3.61 0.120 4.0 0.83 
high 32.66667 3 0.58 0.018 3.9 0.93 
90-180 low 39.5 3 0.71 0.018 4.2 1.05 
med 47 3 1.41 0.030 4.0 1.32 
high 63 3 1.41 0.022 3.8 1.84 
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